companiesRisk of low blood sugar from Novo Nordisk's weekly insulin treatment, regulator saysThe US Food and Drug Administration's staff report has said the use of Novo Nordisk's long-acting weekly insulin had an increased risk of low blood sugar in patients with type 1 diabetes, who are more insulin-dependent.